SALT LAKE CITY, UTAH / ACCESS Newswire / February 6, 2025 /CenExel, a leading network of clinical research sites, proudly ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for non-opioid pain treatments that could help quell the still raging opioid ...

A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

A new non-opioid painkiller, JournaVX, has received approval from the FDA, marking the first new type of pain medication in ...

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...

The Food and Drug Administration on Thursday approved Journavx, a non-opioid painkiller that is the first novel pain drug to win government authorization in more than 20 years. Vertex ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in more than 20 years. “Today’s approval is an important public health ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

Journavx, a new non-opioid pain medication, offers a safer alternative for managing acute pain while reducing the risk of ...